Navigation Links
Growth Factor Aids in Regeneration of Heart Blood Vessel

The latest modality in the treatment of coronary artery disease is to induce hearts to regenerate blood vessels to bypass clogged arteries and damaged tissue. // Unfortunately, clinical trials, which were carried out for two important blood vessel growth factors, fibroblast growth factor- 2 (FGF2) and vascular endothelial growth factor (VEGF), have not yielded sterling outcomes.

Now researchers at Washington University School of Medicine in St. Louis have investigated a third signaling molecule -- called Sonic hedgehog -- that could overcome problems associated with FGF2 and VEGF therapy.

In a report appearing in the June 15 issue of Genes and Development, the team showed that activating hedgehog signals in adult mouse hearts led to an increase in the density of blood vessels in the heart.

Their findings suggest that a drug treatment that turned on or increased hedgehog signals could provide substantial benefit to patients suffering from ischemic heart disease and myocardial infarctions and offer an alternative to invasive procedures like surgery or angioplasty.

About 12 percent of heart patients are not eligible for bypass surgery, which redirects blood around clogged arteries, or for other procedures routinely used to open clogged vessels. That means each year in the United States, 100,000 to 200,000 patients could benefit from having another option for improving blood flow in the heart, according to the study's authors.

'Our study is the first to identify that hedgehog signaling pathways are operational in the developing and mature heart,' says senior author David Ornitz, M.D., Ph.D., the Alumni Endowed Professor of Molecular Biology and Pharmacology.

The hedgehog gene was discovered in fruit flies and named for the spiky appearance of fruit fly embryos with mutations of the gene.

'Hedgehog signaling is a good potential target for growing new vessels in the heart,' says first author Kory Lavine, graduate student in molecular biology and pharmacology and student in the Medical Scientist Training Program. 'The new vessels would provide an alternative route of blood flow, bypassing clogged vessels and other damage. In effect, hedgehog treatment could grow a natural bypass.'

In three large clinical studies, the blood-vessel growth factors FGF2 and VEGF did not result in significant improvement in heart patients who received them.

The Washington University scientists demonstrated that hedgehog has an advantage over these growth factors for possible treatment of heart disease because it specifically stimulates blood vessel formation and does so by orchestrating the expression of multiple other growth factors that work together to build new vessels.

'Research on development in embryonic mouse hearts has shown that the heart needs multiple factors expressed at the right time, in the right amounts and in the right pattern to grow blood vessels that function properly,' Lavine says. 'The best way to achieve that is to use a factor that controls and coordinates the activity of multiple blood-vessel growth factors, and we've found that hedgehog has this ability.'

The researchers showed that hedgehog controlled four growth factors: three VEGF proteins (termed VEGF A, B and C) and a protein called angiopoietin 2. They found that hedgehog is sufficient to stimulate normal development of blood vessels in embryonic mouse hearts -- under hedgehog's control, the blood vessels spread out in an orderly fashion from the top of the ventricles of the growing heart to the bottom.

The researchers are continuing their studies of hedgehog signaling in the heart to determine its utility in treating heart disease.

Source:eurekalert
'"/>




Related medicine news :

1. Anti-Cancer Drug Restores Normal Cell Growth
2. Low-dose Growth Hormone (GH) with diet and exercise may help weight loss
3. Human Growth Hormone Found To be Dangerous For Human Use
4. Stem Cells Found To Offer Promise For Hair Growth
5. Fish Found To Improve Fetal Growth
6. Growth Patterns In Childhood Could Predict Breast Cancer Later In Life
7. Stopping The Growth Of Viruses
8. Stopping The Growth Of Viruses
9. Turmeric Found To Slow Down Melanoma Growth
10. Protein acts as "Master Switch" that cuts off cells Cancer-Growth machinery
11. Record Growth Of Soya-Based Dairy Alternatives Over The Past Year In European Markets
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... , ... Cellairis is a worldwide mobile device and computer repair franchise that ... and Samsung Galaxy devices with premium parts and accessories. Cellairis has recently set-up ... accessibility for customers. While customers do their shopping, Cellairis can accomplish a number of ...
(Date:12/9/2016)... ... ... An inventor from Cana, Va., wanted to fulfill the need for a ... , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates discrimination. It is ... in a matter of minutes, or even seconds. The SAFETY STRAP FOR AMPUTEES is ...
(Date:12/9/2016)... ... 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... summer of 2016. The program was made possible by a Pennsylvania Department of ... Health and Human Services Administration. The broadcast, Use Your Head: Properly Managing ...
(Date:12/8/2016)... Islandia, NY (PRWEB) , ... December 08, 2016 ... ... company, is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture ... published in JMIR Medical Informatics . , Results of the comparative usability ...
(Date:12/8/2016)... Boston (PRWEB) , ... December 08, 2016 , ... ... shareholders with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. ... sponsor of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Research and Markets has announced the addition of the "Endodontic Supplies ... ... the worldwide markets for Endodontic Supplies in US$ Thousand. The report provides separate ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a six-year ...
(Date:12/8/2016)... Dec. 8, 2016   TriNetX , the ... Children,s Hospital signed a membership agreement to ... development of new cures. The TriNetX ... 57 million patients globally, biopharmaceutical companies and contract ... improve protocol design, site selection, patient recruitment, and ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology: